PARP1 inhibitors can also depress METTL3 expression, resulting in a decreased M6A level of LPAR5 mRNA A1881, consequently leading to decreased stability of LPAR5 mRNA and exhibiting a synergistic effect of tumor growth suppression with radiotherapy [44]. The gene discussed is METTL3; the disease is neoplasm.